A Novel Bispecific Antibody Targeting PD-L1 and VEGF With Combined Anti-Tumor Activities
Therapeutic monoclonal antibodies (mAbs) blocking immune checkpoints have been mainly used as monotherapy. Recently, combination therapy targeting multiple immune checkpoints has recently been explored to increase anti-cancer efficacy. Particularly, a single molecule targeting more than one checkpoi...
Enregistré dans:
Auteurs principaux: | Xiaopei Cui, Huifeng Jia, Hong Xin, Lei Zhang, Shi Chen, Simin Xia, Xue Li, Wei Xu, Xiaofang Chen, Yujie Feng, Xiaoyue Wei, Haijia Yu, Yanting Wang, Yifan Zhan, Xiangyang Zhu, Xuemei Zhang |
---|---|
Format: | article |
Langue: | EN |
Publié: |
Frontiers Media S.A.
2021
|
Sujets: | |
Accès en ligne: | https://doaj.org/article/a3b267fa67544fc5a32b0e5de324c6a1 |
Tags: |
Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!
|
Documents similaires
-
Lipid insertion enables targeted functionalization of paclitaxel-loaded erythrocyte membrane nanosystem by tumor-penetrating bispecific recombinant protein
par: Chen H, et autres
Publié: (2018) -
VEGF siRNA delivered by polycation liposome-encapsulated calcium phosphate nanoparticles for tumor angiogenesis inhibition in breast cancer
par: Chen J, et autres
Publié: (2017) -
Efficient and Highly Specific Gene Transfer Using Mutated Lentiviral Vectors Redirected with Bispecific Antibodies
par: Christina L. Parker, et autres
Publié: (2020) -
Site-specific PEGylation of an anti-CEA/CD3 bispecific antibody improves its antitumor efficacy
par: Pan H, et autres
Publié: (2018) -
Simultaneous Inhibition of PD-1 and Stimulation of CD40 Signaling Pathways by Anti-PD-L1/CD40L Bispecific Fusion Protein Synergistically Activate Target and Effector Cells
par: Madhu S. Pandey, et autres
Publié: (2021)